Trimetazidine in addition to optimal medical therapy in patients undergoing coronary PCI does not change events rate at long term.  The ATPCI study was presented at ESC 2020 and simultaneously published in the Lancet. This study randomized coronary PCI patients with stable or acute NSTEMI coronary syndromes to trimetazidine vs. placebo.   What is the rationale…